News Releases
by Year
2017
Dec. 27, 2017 (PDF/143KB) R&D
Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
Dec. 25, 2017 (PDF/215KB) Corporate
Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
Dec. 21, 2017 (PDF/58KB) Corporate
Dissolution of Create Vaccine Company, Ltd.
Dec. 14, 2017 (PDF/100KB) Corporate
Establishment of Bioscience Research Laboratory and Transfer of Functions of Genomic Science Laboratories
Dec. 14, 2017 (PDF/128KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Personnel Change
Dec. 06, 2017 (PDF/300KB) Products
Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Nov. 21, 2017 (PDF/252KB) Licensing
Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Nov. 13, 2017 (PDF/206KB) R&D
Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD
Oct. 30, 2017 (PDF/191KB) Licensing
Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries
Oct. 30, 2017 (PDF/401KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2018
Oct. 30, 2017 (PDF/323KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2018 [Japanese GAAP] (Unaudited)
Oct. 24, 2017 (PDF/243KB) R&D
Kitasato Institute and Sumitomo Dainippon Pharma Sign a Joint Drug Discovery Research Agreement for Infections Caused by Bacteria with Antimicrobial Resistance (AMR)
Oct. 20, 2017 (PDF/348KB) Products
Sunovion Announces Seebri Neohaler (glycopyrrolate) Inhalation Powder is Now Available in the United States
Sep. 27, 2017 (PDF/223KB) Corporate
Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees
Sep. 15, 2017 (PDF/365KB) Products
Sunovion's Aptiom (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
Sep. 06, 2017 (PDF/141KB) Licensing
Sumitomo Dainippon Pharma and Maruishi Pharmaceutical concluded a license agreement for an Antiemetic Candidate Compound
Sep. 01, 2017 (PDF/146KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Sep. 01, 2017 (PDF/247KB) R&D
Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
Aug. 30, 2017 (PDF/105KB) R&D
Sumitomo Dainippon Pharma Submits an Application in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies
Jul. 28, 2017 (PDF/121KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Jul. 28, 2017 (PDF/581KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2018
Jul. 28, 2017 (PDF/152KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2018 [Japanese GAAP] (Unaudited)
Jul. 25, 2017 (PDF/105KB) Corporate
Sumitomo Dainippon Pharma Announces Investment in DEFTA Healthcare Technologies, L.P.
Jul. 14, 2017 (PDF/252KB) Corporate
Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma
Jul. 04, 2017 (PDF/49KB) Corporate
Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S.
Jul. 03, 2017 (PDF/301KB) R&D
Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Jun. 26, 2017 (PDF/75KB) R&D
Sumitomo Dainippon Pharma Announces Unblinding of Phase 3 Study of Napabucasin, a cancer stemness inhibitor, in Patients with Gastric/GEJ Cancer
Jun. 16, 2017 (PDF/125KB) Corporate
Sumitomo Dainippon Pharma announces personnel change
Jun. 09, 2017 (PDF/131KB) R&D
Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression
Jun. 09, 2017 (PDF/110KB) Licensing
Sumitomo Dainippon Pharma Announces Partnership with Zuellig Pharma on its Carbapenem Antibiotic Meropenem for Five Countries of South-East Asia and Hong Kong
Jun. 01, 2017 (PDF/62KB) Sustainability
Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period
May 31, 2017 (PDF/180KB) Products
Toray's Pruritus Treatment REMITCH OD Tablets 2.5 μg to Be Introduced in Japan
May 29, 2017 (PDF/49KB) Finances
Sumitomo Dainippon Pharma Announces Voluntary Adoption of International Financial Reporting Standards (IFRS)
May 29, 2017 (PDF/348KB) R&D
Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease (COPD)
May 18, 2017 (PDF/131KB) R&D
Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2017
May 18, 2017 (PDF/124KB) Corporate
Sumitomo Dainippon Pharma announces personnel change
May 11, 2017 (PDF/122KB) Corporate
Sumitomo Dainippon Pharma Announces Dividends (Including Special Dividends) of Surplus
May 11, 2017 (PDF/55KB) Corporate
Sumitomo Dainippon Pharma announces Changes in Board of Directors and Audit & Supervisory Board
May 11, 2017 (PDF/568KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2017
May 11, 2017 (PDF/597KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2017 [Japanese GAAP] (Unaudited)
May 08, 2017 (PDF/118KB) Corporate
Sumitomo Dainippon Pharma announces personnel change
Apr. 12, 2017 (PDF/81KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder (ADHD)
Apr. 07, 2017 (PDF/87KB) Licensing
Sumitomo Dainippon Pharma Announces Partnership with Bukwang on its Atypical Antipsychotic Agent Lurasidone for Korea
Apr. 06, 2017 (PDF/53KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of TRERIEF, a therapeutic agent for Parkinson's disease, in the Treatment of Patients with Parkinsonism in Dementia with Lewy Bodies (DLB)
Apr. 04, 2017 (PDF/347KB) Products
Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
Mar. 30, 2017 (PDF/109KB) Products
Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH OD TABLETS 2.5μg
Mar. 29, 2017 (PDF/61KB) Corporate
Sumitomo Dainippon Pharma announces Changes in Executive Officers
Mar. 22, 2017 (PDF/73KB) Corporate
Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical, Inc. and Establishment of Global Head of Oncology
Mar. 01, 2017 (PDF/161KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Feb. 28, 2017 (PDF/88KB) Products
Sumitomo Dainippon Pharma Announces the Approval of an Atypical Antipsychotic Blonanserin (Brand Name in Japan: LONASEN) in China
Feb. 28, 2017 (PDF/57KB) R&D
Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a "SAKIGAKE" Product by Japan's Ministry of Health, Labour and Welfare
Feb. 24, 2017 (PDF/29KB) Corporate
Sumitomo Dainippon Pharma announces Changes of Representative Directorsand Executive Officers
Jan. 28, 2017 (PDF/295KB) Products
Sunovion’s Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
Jan. 27, 2017 (PDF/558KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2017
Jan. 27, 2017 (PDF/324KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
Jan. 26, 2017 (PDF/63KB) Corporate
Sumitomo Dainippon Pharma Completes Acquisition of Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
Jan. 23, 2017 (PDF/161KB) R&D
Sumitomo Dainippon Pharma Announces Clinical Data of Investigational Cancer Stemness Inhibitor Napabucasin were presented at 2017 ASCO GI Symposium
Jan. 18, 2017 (PDF/134KB) Sustainability
Sumitomo Dainippon Pharma to Participate in Global Partnership "Access Accelerated" to Address Non-Communicable Diseases
Jan. 14, 2017 (PDF/184KB) R&D
Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo
Jan. 13, 2017 (PDF/240KB) R&D
Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder